Abstract 46P
Background
The drug resistance against chemotherapy and high metastasis rate in triple-negative breast cancer reduce the success of breast cancer treatment. Glutathione S-transferase P1 enzyme (GSTP1) expression increases in cancer cell lines and leads to the development of drug resistance against chemotherapy. The antioxidant chlorophyllin is shown to have an inhibitory effect on GSTP1. The purpose of this study is to investigate the effects of GSTP1 inhibitor chlorophyllin and/or its coadministration with anticancer drug docetaxel on metastatic processes in vitro/in vivo in the 4T1 triple-negative breast cancer cell line and animal model.
Methods
Cell viability, cell cycle, and cell migration were investigated by MTT test, flow cytometry, and wound closure assay, respectively. Matrix metalloproteinase 9 (MMP-9) expression, causing invasion, was determined by Western Blot in the 4T1 cell line and tissue samples. Further, total gelatinase enzyme activity was also detected by gelatin degradation assay. Total GST enzyme activity and glutathione levels of tissue were investigated by colorimetric methods. Micrometastatic foci in liver tissue sections were evaluated by histochemistry.
Results
As a result, coadministration of chlorophyllin and docetaxel significantly inhibited cell migration in vitro. Chlorophyllin significantly reduced the expression of MMP-9 in the tissue samples, and this effect was higher when it is coadministered with docetaxel. In coadministration, a significant decrease was observed in the total gelatinase activity in vivo. It was also determined that chlorophyllin increased in vivo total glutathione levels and decreased GST enzyme activity. Finally, the micrometastases in the liver were reduced by coadministration.
Conclusions
Our results suggest that the coadministration of chlorophyllin and docetaxel may have a potential role in the control of metastatic processes by suppressing cell migration and invasion which is mainly characterized by gelatinase enzyme expression & activity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Hacettepe University Scientific Research Projects Coordination Unit.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
68P - Dendritic polylysine with paclitaxel and triptolide codelivery for enhanced NSCLC ferroptosis through the accumulation of ROS
Presenter: Huae Xu
Session: Poster session 09
69P - Novel monoclonal antibodies can distinguish Cripto-1 from Cripto-3 proteins: Clinical implications and potential new biomarkers
Presenter: Josune Garcia-Sanmartin
Session: Poster session 09
70P - The human intratumor mycobiome is significantly influenced by an individual's race
Presenter: Dan Coster
Session: Poster session 09
71P - Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
Presenter: Lillian Skidmore
Session: Poster session 09
72P - Impact of extended panel of genes for germline cancer testing
Presenter: Shaheenah Dawood
Session: Poster session 09
73P - Preclinical and clinical presentation of the nerve-driven tumor spread
Presenter: Dawid Sigorski
Session: Poster session 09
74P - Characterization of ERBB2 variation and their association with immune response in solid tumours
Presenter: Dong Wang
Session: Poster session 09
75P - Double-stranded RNA transfection induced anti-tumour effect mediated by dual RIG-I and TLR-3 immune pathways
Presenter: Jiayu Tai
Session: Poster session 09
76P - Improvement of whole-cell cancer vaccine anti-tumor effect by different injection methods
Presenter: Chin yang Chang
Session: Poster session 09
77P - Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Presenter: Ragnhild Åsberg
Session: Poster session 09